ReviewInternational journal of molecular sciences2021
Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma.BMC gastroenterology · 2025Pooled it
- Pooled it
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- Transarterial chemoembolization (TACE) with or without immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis of randomized clinical trials.ESMO gastrointestinal oncology · 2026Review
- Characterization of hepatocellular carcinoma patient-derived organoids from patients receiving transarterial chemoembolization as a model for preclinical drug response assessment.Scientific reports · 2026Article
- Prediction of mRECIST tumor response at firstfollow-up after DEB-TACE using a combined radiomics-clinical model and explainability methods.Clinical and experimental medicine · 2026Article
- Dual-targeted microspheres reshape the metabolic-immune microenvironment to reverse post-embolization dilemmas in hepatocellular carcinoma.Cell reports. Medicine · 2026Article
- Impact of Procedural Quality on Outcomes of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicenter Study.Liver cancer · 2026Article
- Article
- Prediction of early treatment response to drug-eluting beads chemoembolization for hepatocellular carcinoma using machine learning.Frontiers in pharmacology · 2026Article
- Synergistic Effect of Doxorubicin-Thermo-Iodized Oil Pickering Emulsions on the Interventional Embolization-Chemotherapy- Immunity of VX2 Rabbit Liver Cancer.International journal of nanomedicine · 2026Article
- Radioembolization in Hepatocellular Carcinoma: Indications and Outcomes.Journal of gastrointestinal cancer · 2025Review
- Double-targeted liposomes coated with matrix metallopeptidase-2-responsive polypeptide nanogel for chemotherapy and enhanced immunotherapy against cervical cancer.Materials today. Bio · 2025Article
- Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients.Therapeutic advances in medical oncology · 2025Article
- The Synergistic Mechanisms and Prospects of Transarterial Chemoembolization Combined with Immunotherapy for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Review
- Research Trends on Nanomaterials and Hepatocellular Carcinoma From 1999 to 2024: A Bibliometric Analysis.Drug design, development and therapy · 2025Article
- Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Molecular Targets and Nano-Technological Approaches in the Treatment of Hepatic Carcinoma.Current cancer drug targets · 2025Review
- Development and validation of a model for predicting who can benefit from multiple TACE in HCC patients.Clinical and experimental medicine · 2024Article
- Relaxin combined with transarterial chemoembolization achieved synergistic effects and inhibited liver cancer metastasis in a rabbit VX2 model.Journal of cancer research and clinical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because diagnostic tools for discriminating between hepatocellular carcinoma (HCC) and advanced cirrhosis are poor, HCC is often detected in a stage where transarterial chemoembolization (TACE) is the best treatment option, even though it provides a poor survival gain. Despite having been used worldwide for several decades, TACE still has many limitations. First, there is a vast heterogeneity in the cellular composition and metabolism of HCCs as well as in the patient population, which renders it difficult to identify patients who would benefit from TACE. Often the delivered drug does not penetrate sufficiently selectively and deeply into the tumour and the drug delivery system is not releasing the drug at an optimal clinical rate. In addition, therapeutic effectiveness is limited by the crosstalk between the tumour cells and components of the cirrhotic tumour microenvironment. To improve this widely used treatment of one of our most common and deadly cancers, we need to better understand the complex interactions between drug delivery, local pharmacology, tumour targeting mechanisms, liver pathophysiology, patient and tumour heterogeneity, and resistance mechanisms. This review provides a novel and important overview of clinical data and discusses the role of the tumour microenvironment and lymphatic system in the cirrhotic liver, its potential response to TACE, and current and possible novel DDSs for locoregional treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.